AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01762709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The VT 8 ml/kg group
Description: the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study NCT04142970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSK3486
Description: HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
Study NCT00540618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
Study NCT03826784 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BHA
Description: BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
Study NCT01155167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin and lidocaine
Description: Topical Nitroglycerin and lidocaine
Study NCT01155167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04796064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-intensity aerobic training
Description: A low-intensity aerobic training group started with 15 minutes of warm-up, which includes static stretching of the upper and lower limb muscles. then participants were instructed to do 30 minutes of low-intensity aerobic training exercises, which include 20 minutes on the treadmill and 10 minutes of cycle ergometer, followed by 10 minutes of cool down.~- In high-intensity training (HAT) the same protocol has been followed, but the intensity of exercises was fixed between 60% to 80 % of maximum heart rate. The strength training includes major group muscles such as shoulder flexors, extensors, and abductors, elbow flexors and extensors, hip flexors\& extensors, knee flexors\&extensors, abdominal and back muscles also were trained. Each group of muscles was trained for 10 repetitions for 3 sets with a rest period of 5 minutes.
Study NCT02572739 — intervention group
Intervention type: DEVICE
Intervention: PICCO
Description: measurements based on thermodilution
Study NCT02572739 — intervention group
Intervention type: DEVICE
Intervention: NICCOMO
Description: measurements based on impedance
Study NCT03757390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 5/160mg, Crestor® tab 10mg
Description: co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
Study NCT03757390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 5/160/10mg
Description: Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
Study NCT00853970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic Solution
Description: sterile ophthalmic solution
Study NCT00853970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: sterile ophthalmic solution
Study NCT03658876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose Solution for Injection
Description: 200mg iron sucrose given on 5 successive haemodialysis sessions
Study NCT03658876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Beta
Description: Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
Study NCT03007004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (2500 units / vial)
Description: BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
Study NCT03007004 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Physiological saline
Description: Saline solution was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with saline (0.2 ml). In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of saline (0.1 ml). A total of 1.0 ml of saline was injected into one hand. Injections were performed using a 30-gauge needle.
Study NCT02551991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nal-IRI
Study NCT02551991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Study NCT02551991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT02551991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (insulin 287)
Description: Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase-4 inhibitors
Description: Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptidyl peptidase-4 inhibitors
Description: Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
Study NCT03751657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (insulin glargine)
Description: Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
Study NCT01588418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
Study NCT01588418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered in random order 30 min before OGTT-PET study in the same subject
Study NCT02601573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
Study NCT02601573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: SOF 400 mg tablet taken q.d. by mouth in the morning with food.
Study NCT03393026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 40-160 mg/day for 6 weeks
Study NCT01052857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture application
Study NCT02921425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient health record
Description: The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
Study NCT01694043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Foods
Description: While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
Study NCT01694043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unhealthy Snack Foods
Description: While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
Study NCT00643383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination drug (Acetaminophen + Tramadol)
Study NCT00643383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02781792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: -Given standard of care
Study NCT02781792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Brain
Description: * 23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire \[2\] that includes 27 items.~* Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~* The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia.
Study NCT02781792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActTrust Condor Instrument Watch
Description: -Will be required to wear 24 hours per day and will only be removed at specified data collection time points
Study NCT02229734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
Study NCT02229734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression
Description: Leuprolide 45mg every 6 months for a total of 18 months
Study NCT02797119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid 1 g (TA1)
Description: 1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
Study NCT02797119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid 0.5 g (TA1/2)
Description: 0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
Study NCT02797119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (TA0)
Study NCT04529655 — intervention group
Intervention type: DEVICE
Intervention: Capillary Refill Assessment
Description: Device to quantify capillary refill time
Study NCT00961987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative model
Description: Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
Study NCT00961987 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
Study NCT03181113 — intervention group
Intervention type: DRUG
Intervention: Peginterferon Alfa-2B
Description: pre-received standard peginterferon alfa-2b therapy
Study NCT03132727 — intervention group
Intervention type: OTHER
Intervention: Pharyngo laryngeal MRI
Description: Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure.
Study NCT04067180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation with a haplo-identical family donor graft
Description: The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil.
Study NCT04067180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic stem cell transplantation with a matched unrelated donor graft
Description: Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied.
Study NCT01139437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose HPIV2 Vaccine
Description: 10\^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
Study NCT01303224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, low dose, once daily, for 8 weeks
Study NCT01303224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, intermediate dose, once daily, for 8 weeks
Study NCT01303224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, high dose, once daily, for 8 weeks
Study NCT01303224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
Study NCT03283605 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
Study NCT03283605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
Study NCT03283605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
Study NCT04075812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Stimulator
Study NCT01139437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose HPIV2 vaccine
Description: 10\^5 TCID50 administered in a single dose
Study NCT01139437 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT01689792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOVIPREP
Study NCT01689792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CitraFleet
Study NCT00291057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MALG
Description: 30 minute application
Study NCT00868010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: 5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
Study NCT00868010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
Study NCT00907413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP and Photodynamic Therapy
Description: Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
Study NCT03165604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard information
Description: The participates will be given a standard information regarding the water drink before physical activity
Study NCT00907413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP only
Description: Endoscopic retrograde cholangiopancreatography and stenting.
Study NCT00907413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP only
Description: Endoscopic retrograde cholangiopancreatography and stenting.
Study NCT01085825 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D & C abortion
Description: Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
Study NCT00830401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of predefined abnormality by hysteroscopic surgery
Description: * Polyp resection with Hysteroscopic scissors or Versapoint~* Resection of myoma with Resectoscope Storz or Versapoint~* Septum resection with Resectoscope Storz or Versapoint~* Resection of adhesions with Hysteroscopic scissors or Versapoint
Study NCT00830401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacinum/Doxycycline
Description: Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
Study NCT02612337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg OTO-104
Study NCT02612337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study NCT00099047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given PO
Study NCT00099047 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT00099047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00099047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03165604 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive information
Description: The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity
Study NCT02146495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous EEG and fMRI recordings